Physician profile
David D Wine
NPI 1811985542
$1,365.82
in general payments reported to CMS, 2019-2025
20 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $728 · 2020: $191 · 2022: $16.80 · 2023: $124 · 2024: $39.63 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $429.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $269.76 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $149.88 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $148.14 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $124.36 | 2019-2024 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $119.95 | 2019-2025 | Shingrix |
| Astellas Pharma US INC | $101.30 | 2019-2020 | |
| Abbvie INC. | $69.06 | 2023-2025 | Vraylar |
| Pfizer INC. | $63.13 | 2019-2025 | |
| Hologic Sales and Service, LLC | $51.75 | 2025 | Aptima |
| E.R. Squibb & Sons, L.L.C. | $43.05 | 2019-2020 | |
| Amarin Pharma, INC. | $42.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.41 | 2020-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $29.79 | 2019 | |
| Axsome Therapeutics, INC. | $21.57 | 2023 | Sunosi |
| Mannkind Corporation | $21.33 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $16.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.15 | 2019 | |
| Eisai INC. | $15.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.46 | 2020 | |
| Biowound Solutions, INC. | $10.70 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.